Pacira Biosciences
Non-opioid pain management innovations.
- Healthcare
- pharmaceutical
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $300m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 29 % | 23 % | 1 % | 4 % | 6 % | 11 % | 10 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 27 % | 18 % | 25 % | 27 % | 28 % | 29 % | 31 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 8 % | 2 % | 6 % | (14 %) | 4 % | 9 % | 12 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 10 % | 13 % | 11 % | 12 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Pacira Biosciences, Inc. is a pharmaceutical company that provides non-opioid pain management and regenerative health solutions.
The company's flagship product, EXPAREL, is a local analgesic that is used for postsurgical pain management. EXPAREL is a bupivacaine liposome injectable suspension that is administered at the time of surgery. The company also markets iovera, a handheld device that uses cryoanalgesia to temporarily block pain signals from peripheral nerves.
Pacira Biosciences serves hospitals, ambulatory surgery centers, and physicians in the United States. The company's business model is based on the sale of its products to these customers. Pacira Biosciences generates revenue through the sale of EXPAREL and iovera.
The company is focused on expanding the use of its products in new indications and geographies. Pacira Biosciences is also developing new products to address unmet needs in pain management and regenerative health.
Keywords: non-opioid pain management, regenerative health, EXPAREL, iovera, cryoanalgesia, postsurgical pain, pharmaceuticals, medical devices, healthcare, life sciences
Tech stack
Investments by Pacira Biosciences
Edit
